The Vaccines Market Outlook To 2014 Competitive landscape, pipeline analysis, growth opportunities and market forecasts Report Overview A combination of new biotechnology research techniques and manufacturing technologies has reinvigorated the global vaccines industry. Vaccines are now targeting larger markets following increasing demand and improved profitability. The WHO estimates that more than 75 vaccines are currently at various stages of development for a range of diseases including AIDs, diarrhoea, pneumococcal disease, cervical cancer and smoking. 'The Vaccines Market Outlook To 2014' is a report published by Business Insights that provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. The competitive landscape of the market is examined, based on an analysis of portfolio performance, pipeline strength and growth strategies for each major vaccine manufacturer. This report also reviews the factors and underlying trends that are currently shaping market development, and provides forecasts for currently marketed and key pipeline products over the 2009-14 period. Key Findings The global vaccines market generated sales of $11.1bn in 2008, an increase of 0.5% over 2007. Merck/Sanofi-Aventis' Gardasil led the market with sales of $1.6bn in 2008, while Wyeth's Prevnar followed with $1.4bn. The top 10 brands accounted for 56.7% of the market. Pneumococcal vaccines led the pediatric vaccines segment in 2008, with Wyeth's Prevnar accumulating sales of $1.4bn. These were followed by DTP vaccines led by GSK's Infanrix Hexa, which registered $281m sales. Emerging segments in the pediatric space include MMRV (MMR+ varicella), rotaviral and meningococcal vaccines. HPV vaccines formed the single largest adult vaccines segment in 2008 with Merck/Sanofi-Aventis' Gardasil posting sales of $1.6bn. These were followed by the fragmented influenza segment, which continues to be a major sales driver for vaccine developers. Hepatitis vaccines also captured a major share of the adult vaccines market. Wyeth's Prevnar 13vPnC and Novartis' Menveo are among the most promising vaccines in the industry pipeline. GSK's Cervarix is likely to attain blockbuster status in 2011, having received approval in the US market. The latter part of the forecast period will witness the launch of Novartis' MenB, for the prevention of Neisseria meningitidis serogroup B infection. Use this report to ' Quantify infant, catch up, adolescent, adult and elderly vaccine target populations across France, Germany, Italy, Spain, the UK, the US, Japan, South Korea, Turkey, Russia, Mexico, Brazil, China and India. ' Assess leading pediatric and adult vaccine brands across major indications based on efficacy, adverse effects and ongoing trials, and evaluate the impact of recent events upon product performance. ' Compare the market performance and strategic positioning of major vaccine companies' product portfolios with this report's evaluation of the franchises of Merck, GSK, Wyeth, Sanofi-Aventis and Novartis. ' Forecast sales for key currently marketed and leading pipeline vaccines over the period 2009'14, assess the latest trends influencing R&D and measure the developmental progress of DNA and therapeutic vaccines. Explore issues including... The impact of prophylactic cancer vaccines. Since the launch of Merck's Gardasil and GSK's Cervarix, the market has expanded to include prophylactic vaccines against cancer. These vaccines have registered revenues of almost $1.8bn since launch. The emergence of therapeutic vaccines. Therapeutic vaccines will redefine the vaccines market, which has predominantly been prophylactic in nature until date. Considering the unavailab

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
The Vaccines Market Outlook To 2014: Competitive landscape,
pipeline analysis, growth opportunities and market forecasts
Published on July 2009
Report Summary
The Vaccines Market Outlook To 2014 Competitive landscape, pipeline analysis, growth opportunities and market forecasts Report
Overview A combination of new biotechnology research techniques and manufacturing technologies has reinvigorated the global
vaccines industry. Vaccines are now targeting larger markets following increasing demand and improved profitability. The WHO
estimates that more than 75 vaccines are currently at various stages of development for a range of diseases including AIDs,
diarrhoea, pneumococcal disease, cervical cancer and smoking. 'The Vaccines Market Outlook To 2014' is a report published by
Business Insights that provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines
market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key
growth areas and leading products through to 2014. The competitive landscape of the market is examined, based on an analysis of
portfolio performance, pipeline strength and growth strategies for each major vaccine manufacturer. This report also reviews the
factors and underlying trends that are currently shaping market development, and provides forecasts for currently marketed and key
pipeline products over the 2009-14 period. Key Findings The global vaccines market generated sales of $11.1bn in 2008, an
increase of 0.5% over 2007. Merck/Sanofi-Aventis' Gardasil led the market with sales of $1.6bn in 2008, while Wyeth's Prevnar
followed with $1.4bn. The top 10 brands accounted for 56.7% of the market. Pneumococcal vaccines led the pediatric vaccines
segment in 2008, with Wyeth's Prevnar accumulating sales of $1.4bn. These were followed by DTP vaccines led by GSK's Infanrix
Hexa, which registered $281m sales. Emerging segments in the pediatric space include MMRV (MMR+ varicella), rotaviral and
meningococcal vaccines. HPV vaccines formed the single largest adult vaccines segment in 2008 with Merck/Sanofi-Aventis'
Gardasil posting sales of $1.6bn. These were followed by the fragmented influenza segment, which continues to be a major sales
driver for vaccine developers. Hepatitis vaccines also captured a major share of the adult vaccines market. Wyeth's Prevnar 13vPnC
and Novartis' Menveo are among the most promising vaccines in the industry pipeline. GSK's Cervarix is likely to attain blockbuster
status in 2011, having received approval in the US market. The latter part of the forecast period will witness the launch of Novartis'
MenB, for the prevention of Neisseria meningitidis serogroup B infection. Use this report to ' Quantify infant, catch up,
adolescent, adult and elderly vaccine target populations across France, Germany, Italy, Spain, the UK, the US, Japan, South Korea,
Turkey, Russia, Mexico, Brazil, China and India. ' Assess leading pediatric and adult vaccine brands across major indications based
on efficacy, adverse effects and ongoing trials, and evaluate the impact of recent events upon product performance. ' Compare the
market performance and strategic positioning of major vaccine companies' product portfolios with this report's evaluation of the
franchises of Merck, GSK, Wyeth, Sanofi-Aventis and Novartis. ' Forecast sales for key currently marketed and leading pipeline
vaccines over the period 2009'14, assess the latest trends influencing R&D and measure the developmental progress of DNA and
therapeutic vaccines. Explore issues including... The impact of prophylactic cancer vaccines. Since the launch of Merck's
Gardasil and GSK's Cervarix, the market has expanded to include prophylactic vaccines against cancer. These vaccines have
registered revenues of almost $1.8bn since launch. The emergence of therapeutic vaccines. Therapeutic vaccines will redefine the
vaccines market, which has predominantly been prophylactic in nature until date. Considering the unavailability of comprehensive
therapeutic measures for indications such as cancer and HIV/AIDS, these therapy areas are a top priority for those developing such
vaccines. Next generation vaccine engineering. The vaccines market has transitioned from traditional egg-based cultures and
aluminum adsorption techniques to large scale cell culture-based production and targeted adjuvant technology. Influenza vaccine
makers are concentrating on cell culture-based production to meet the rising demand for these vaccines. Sales potential for
seasonal influenza vaccines. Despite the large number of players in the seasonal influenza market, the segment holds significant
market opportunity due to an insufficient supply of vaccines. The demand for influenza vaccines is substantial when considering the
requirement for coverage across all population segments. Discover... ' What will be the major growth indications in the vaccines
market over 2009'14' ' What are the current trends across DTP, pneumococcal, MMR, rotaviral, meningococcal, hepatitis, influenza,
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 1/10

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
HPV and other infections within the seven major markets' ' What are the most promising candidate vaccines currently in clinical
development' ' What is the commercial potential of key pipeline candidates through to 2014' ' Which companies are best positioned
to succeed in the vaccines market over 2009'14' ' What is the forecast market size and growth rate over the period 2009'14 across
the global vaccines market' ' What are the significant market and pipeline developments that may shape the corporate strategies of
leading companies'
Table of Content
Table of Contents
The Western European Gas Market Outlook 2009
Chapter 1 Austria 14
Market summary 14
Supply and demand balance 15
Supply overview 16
Demand overview 18
Regulatory structure 20
Wholesale trading 22
Infrastructure 23
Pipelines 23
Storage 24
Chapter 2 Belgium 28
Market summary 28
Supply and demand balance 29
Supply overview 30
Demand overview 31
Regulatory structure 33
Wholesale trading 34
Infrastructure 35
Pipelines 35
LNG 37
Storage 38
Chapter 3 Cyprus 40
Market summary 40
Chapter 4 Denmark 44
Market summary 44
Supply and demand balance 45
Supply overview 46
Demand overview 47
Regulatory structure 48
Wholesale trading 49
Infrastructure 50
Storage 51
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 2/10

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Chapter 5 Finland 54
Market summary 54
Supply and demand balance 55
Supply overview 56
Demand overview 56
Regulatory structure 58
Chapter 6 France 62
Market summary 62
Supply and demand balance 63
Supply overview 64
Demand overview 65
Regulatory structure 67
Wholesale trading 68
Infrastructure 69
LNG 69
Pipeline infrastructure 69
Storage 71
Chapter 7 Germany 74
Market summary 74
Supply and demand balance 75
Supply overview 76
Demand overview 77
Regulatory structure 79
Wholesale trading 82
Infrastructure 83
Pipelines 83
Storage 86
Chapter 8 Greece 88
Market summary 88
Supply and demand balance 89
Supply overview 90
Demand overview 91
Regulatory structure 93
Infrastructure 94
Pipelines 94
LNG 96
Chapter 9 Ireland 98
Market summary 98
Supply and demand balance 99
Supply overview 100
Demand overview 102
Regulatory structure 104
Infrastructure 105
Pipelines 105
Storage 106
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 3/10

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Chapter 10 Italy 110
Market summary 110
Supply overview 112
Demand overview 113
Regulatory structure 115
Wholesale trading 118
POGAS 118
IGEX 118
Infrastructure 119
Pipelines 119
Storage 121
LNG 122
Chapter 11 Luxembourg 126
Market summary 126
Supply and demand balance 127
Supply overview 128
Demand overview 128
Regulatory structure 130
Infrastructure 130
Chapter 12 Malta 134
Market summary 134
Chapter 13 The Netherlands 136
Market summary 136
Supply and demand balance 137
Supply overview 138
Demand overview 140
Regulatory structure 141
Wholesale trading 143
Infrastructure 144
Pipelines 144
Storage 145
LNG 146
Chapter 14 Norway 150
Market summary 150
Supply and demand balance 151
Supply overview 152
Demand overview 153
Regulatory structure 154
Infrastructure 156
Chapter 15 Portugal 160
Market summary 160
Supply and demand balance 161
Supply overview 162
Demand overview 163
Regulatory structure 164
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 4/10

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Infrastructure 166
Pipelines 166
LNG 166
Storage 167
Gas fired power 167
Chapter 16 Spain 170
Market summary 170
Supply and demand balance 171
Supply overview 172
Demand overview 174
Regulatory structure 175
Wholesale trading 176
Infrastructure 177
Pipeline 177
Pipeline developments 178
LNG 178
Storage 179
Chapter 17 Sweden 182
Market summary 182
Supply and demand balance 183
Supply overview 184
Demand overview 184
Regulatory structure 186
Infrastructure 187
Pipelines 187
Chapter 18 Switzerland 190
Market summary 190
Supply and demand balance 191
Supply overview 192
Demand overview 193
Regulatory structure 195
Infrastructure 197
Pipeline 197
Chapter 19 United Kingdom 200
Market summary 200
Supply and demand balance 201
Supply overview 202
Demand overview 204
Regulation 205
Wholesale trading 207
Infrastructure 208
Pipelines 208
LNG 210
Storage 211
Appendix 213
Definitions 213
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 5/10

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
List of Figures
Figure 1.1: Austria, gas production (bcm), 1990-2008e 17
Figure 1.2: Austria, gas import supply sources (%), 2008e 17
Figure 1.3: Austria, gas sectoral demand (%), 2008e 18
Figure 1.4: Austria, gas historical and forecast demand (bcm), 1990-2020 19
Figure 1.5: Austria, gas grid 25
Figure 2.6: Belgium, total gas import (bcm), 1990-2008e 30
Figure 2.7: Belgium, gas pipeline import supply sources (%), 2008e 31
Figure 2.8: Belgium, gas sectoral demand (%), 2008e 32
Figure 2.9: Belgium, gas historical and forecast demand (bcm), 1990-2020 32
Figure 4.10: Denmark, gas production (bcm), 1990-2008e 46
Figure 4.11: Denmark, gas sectoral demand (%), 2008e 47
Figure 4.12: Denmark, gas historical and forecast demand (bcm), 1990-2020 48
Figure 5.13: Finland, gas sectoral demand (%), 2008e 57
Figure 5.14: Finland, historical and forecast demand (bcm), 1990-2020 57
Figure 5.15: Finland, gas grid 59
Figure 6.16: France, gas production (bcm), 1990-2008e 64
Figure 6.17: France, gas import supply sources (%), 2008e 65
Figure 6.18: France, gas sectoral demand (%), 2008e 66
Figure 6.19: France, gas historical and forecast demand (bcm), 1990-2020 66
Figure 6.20: France, transmission grid 72
Figure 7.21: Germany, gas production (bcm), 1990-2008e 77
Figure 7.22: Germany, gas sectoral demand (%), 2008e 78
Figure 7.23: Germany, gas historical and forecast demand (bcm), 1990-2020 78
Figure 8.24: Greece, gas production (bcm), 1990-2008e 90
Figure 8.25: Greece, gas import supply sources (%), 2008e 91
Figure 8.26: Greece, gas sectoral demand (%), 2008e 92
Figure 8.27: Greece, gas historical and forecast demand (bcm), 1990-2020 92
Figure 8.28: Greece, gas grid 96
Figure 9.29: Ireland, gas production (bcm), 1990-2008e 102
Figure 9.30: Ireland, gas sectoral demand (%), 2008e 103
Figure 9.31: Ireland gas, historical and forecast demand (bcm), 1990-2020 103
Figure 10.32: Italy, gas production (bcm), 1990-2008e 112
Figure 10.33: Italy, gas import supply sources (%), 2008e 113
Figure 10.34: Italy, gas sectoral demand (%), 2008e 114
Figure 10.35: Italy, gas historical and forecast demand (bcm), 1990-2020 114
Figure 10.36: Italy, Gas Infrastructure 124
Figure 11.37: Luxembourg, gas import supply sources (%), 2008e 128
Figure 11.38: Luxembourg, gas sectoral demand (%), 2008e 129
Figure 11.39: Luxembourg, gas historical and forecast demand (bcm), 1990-2020 129
Figure 11.40: Luxembourg, gas grid 131
Figure 13.41: The Netherlands, gas production (bcm), 1990-2008e 139
Figure 13.42: The Netherlands, gas import supply sources (%), 2007e 139
Figure 13.43: The Netherlands, gas sectoral demand (%), 2008e 140
Figure 13.44: The Netherlands, gas historical and forecast demand (bcm), 1990-2020 141
Figure 13.45: The Netherlands, gas network 146
Figure 14.46: Norway, gas production (bcm), 1990-2008e 152
Figure 14.47: Norway, gas sectoral demand (%), 2008e 153
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 6/10

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Figure 14.48: Norway, gas historical and forecast demand (bcm), 1990-2020 154
Figure 14.49: Norway, gas export infrastructure 157
Figure 15.50: Portugal, gas import supply sources, 2008e 162
Figure 15.51: Portugal, gas sectoral demand (%), 2008e 163
Figure 15.52: Portugal, gas historical and forecast demand (bcm), 1990-2020 164
Figure 16.53: Spain, gas production (bcm), 1990-2008e 173
Figure 16.54: Spain, gas import supply sources (%), 2008e 173
Figure 16.55: Spain, gas sectoral demand (%), 2008e 174
Figure 16.56: Spain, gas historical and forecast demand (bcm), 1990-2020 175
Figure 16.57: Spain, gas grid 179
Figure 17.58: Sweden, gas sectoral demand (%), 2008e 185
Figure 17.59: Sweden, gas historical and forecast demand (bcm), 1990-2020 185
Figure 17.60: Sweden, gas grid 188
Figure 18.61: Switzerland, gas import supply sources (%), 2008e 193
Figure 18.62: Switzerland, gas sectoral demand (%), 2008e 194
Figure 18.63: Switzerland, gas historical and forecast demand (bcm), 1990-2020 195
Figure 18.64: Switzerland, gas grid 198
Figure 19.65: UK, gas production (bcm), 1990-2008e 203
Figure 19.66: UK, gas import supply sources (%), 2008e 203
Figure 19.67: UK, gas sectoral demand (%), 2008e 204
Figure 19.68: UK, gas historical and forecast demand (bcm), 1990-2020 205
Figure 19.69: UK, gas grid 212
List of Tables
Table 1.1: Austria, Gas supply and demand balance (bcm), 2007-08e* 15
Table 1.2: Austria, storage sites 25
Table 2.3: Belgium, gas supply and demand balance (bcm), 2007-08e* 29
Table 2.4: Belgium, storage sites 38
Table 4.5: Denmark, gas supply and demand balance (bcm), 2007-08e* 45
Table 4.6: Denmark, storage sites 51
Table 5.7: Finland, gas supply and demand balance (bcm), 2007-08e* 55
Table 6.8: France, gas supply and demand balance (bcm), 2007-08e* 63
Table 6.9: France, LNG infrastructure (bcm) 69
Table 6.10: France, LNG infrastructure 71
Table 7.11: Germany, gas supply and demand balance (bcm), 2007-08e* 75
Table 7.12: Germany, storage sites 86
Table 8.13: Greece, gas supply and demand balance (bcm), 2007-08e* 89
Table 9.14: Ireland, gas supply and demand balance (bcm), 2007-08e* 99
Table 9.15: Ireland, transmission grid 107
Table 10.16: Italy, gas supply and demand balance (bcm), 2007-08e* 111
Table 10.17: Italy, storage sites 122
Table 10.18: Italy, LNG infrastructure 123
Table 11.19: Luxembourg, Gas supply and demand balance (bcm), 2007-08e* 127
Table 13.20: The Netherlands, gas supply and demand balance (bcm), 2007-08e* 137
Table 13.21: The Netherlands, storage sites 145
Table 14.22: Norway, gas supply and demand balance (bcm), 2007-08e* 151
Table 15.23: Portugal, gas supply and demand balance (bcm), 2007-08e* 161
Table 16.24: Spain, gas supply and demand balance (bcm), 2007-08e* 171
Table 16.25: Spain, LNG infrastructure 178
Table 16.26: Spain, storage sites 180
Table 17.27: Sweden, gas supply and demand balance (bcm), 2007-08e* 183
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 7/10

8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 18.28: Switzerland, Gas supply and demand balance (bcm), 2007-08e* 191
Table 19.29: UK, gas supply and demand balance (bcm), 2007-08e* 201
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 8/10

9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market
forecasts
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 3 835.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 9/10

10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts Page 10/10